Skip to main content
padlock icon - secure page this page is secure

Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy

Buy Article:

$106.65 + tax (Refund Policy)

A gold/mesoporous silica hybrid nanoparticle (GoMe), which possesses the best of both conventional gold nanoparticles and mesoporous silica nanoparticles, such as excellent photothermal converting ability as well as high drug loading capacity and triggerable drug release, has been developed. In contrast to gold nanorod and other heat generating gold nanoparticles, GoMe is photothermal stable and can be repetitively activated through NIR irradiation. Doxorubicin loaded GoMe ([email protected]) is sensitive to both NIR irradiation and intracellularly elevated redox potential. [email protected] coupled with NIR irradiation exhibits a synergistic effect of photothermal therapy and chemotherapy in killing cancer cells. Furthermore, 64Cu-labeled GoMe can successfully detect the existence of clinically relevant spontaneous lung tumors in a urethane-induced lung cancer mouse model through PET imaging. Altogether, GoMe can be utilized as an effective theranostic platform for cancer therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: CANCER DETECTION; GOLD NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; PHOTOTHERMAL THERAPY; REDOX RESPONSIVE

Document Type: Research Article

Publication date: March 1, 2016

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more